Asset profile
Palbociclib · Ibrance
Small molecule
Approvedregulatory verdict
Evidence outlook
Approved: HR+/HER2- Metastatic Breast Cancer
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
65 competitors in this universe: 5 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication.
Unlock with Research ↗
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Palbociclib (Ibrance): this drug | Approved | Small molecule | CDK4 and CDK6 | ||
| Abemaciclib (Verzenio) | Approved | Small molecule | CDK4 and CDK6 | ||
| Ribociclib | Approved | Small molecule | CDK4 and CDK6 | ||
| BPI-16350 | Phase 3 | Small molecule | CDK4 and CDK6 | ||
| Dalpiciclib | Phase 3 | Small molecule | CDK4 and CDK6 | ||
| BPI-1178 | Phase 1/2 | Small molecule | CDK4 and CDK6 | ||
| Alpelisib (BYL719) | Approved | Small molecule | PI3K-alpha | ||
| Anastrozole | Approved | Small molecule | Aromatase | ||
| Capecitabine | Approved | Small molecule | Fluoropyrimidine (antimetabolite) | ||
| Capivasertib | Approved | Small molecule | AKT (inhibitor) | ||
| Datopotamab Deruxtecan | Approved | Antibody–drug conjugate | TROP2 | ||
| Denosumab | Approved | Monoclonal antibody | RANKL | ||
| Docetaxel | Approved | Small molecule | Microtubules (tubulin) | ||
| Elacestrant | Approved | Small molecule | Estrogen receptor | ||
| Eribulin Mesylate | Approved | Small molecule | Tubulin / microtubules | ||
| Everolimus | Approved | Small molecule | mTOR kinase, mTOR (mTORC1) (inhibitor) |
…and 50 more. Research shows the complete landscape.
Research
Unlock with Research ↗Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(72 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (14)
October 2026 (1)
Phase 1/2Renal Cell CarcinomaActive not recruiting
Est. primary completion 2026-10-22 · NCT05468697 · CT.gov ↗
What to watch
November 2026 (1)
Phase 1/2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2026-11 · NCT02605486 · CT.gov ↗
What to watch
December 2026 (12)
Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2026-12 · NCT02738866 · CT.gov ↗
What to watch
Phase 2Nasopharyngeal CarcinomaNot yet recruiting
Est. primary completion 2026-12 · NCT04605562 · CT.gov ↗
What to watch
Phase 3HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2026-12 · NCT03820830 · CT.gov ↗
What to watch
Phase 1Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C MutationActive not recruiting
Est. primary completion 2026-12-17 · NCT04185883 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2026-12-27 · NCT05563220 · CT.gov ↗
What to watch
Early phase / not applicableHR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2026-12-27 · NCT04216576 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2026-12-30 · NCT03573648 · CT.gov ↗
What to watch
Phase 3HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2026-12-30 · NCT05909397 · CT.gov ↗
What to watch
Phase 1HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2026-12-31 · NCT03006172 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2026-12-31 · NCT04553133 · CT.gov ↗
What to watch
Phase 2Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid TumorsRecruiting
Est. primary completion 2026-12-31 · NCT03297606 · CT.gov ↗
What to watch
Phase 2Solid Tumor, Precision MedicineRecruiting
Est. primary completion 2026-12-31 · NCT06739395 · CT.gov ↗
What to watch
2027 (30)
January 2027 (1)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-01-10 · NCT06207734 · CT.gov ↗
What to watch
February 2027 (1)
Phase 2Malignant Female Reproductive System Neoplasm, Malignant Solid Neoplasm, Recurrent Malignant Female Reproductive System Neoplasm …Recruiting
Est. primary completion 2027-02-20 · NCT06126276 · CT.gov ↗
What to watch
March 2027 (1)
Phase 1/2EGFR Tyrosine Kinase Inhibitors Plus Cyclin-dependent Kinase 4/6 InhibitorRecruiting
Est. primary completion 2027-03 · NCT06947811 · CT.gov ↗
What to watch
April 2027 (2)
May 2027 (1)
Phase 2Advanced Dedifferentiated Liposarcoma, Locally Advanced Dedifferentiated Liposarcoma, Metastatic Dedifferentiated Liposarcoma …Active not recruiting
Est. primary completion 2027-05-31 · NCT05694871 · CT.gov ↗
What to watch
June 2027 (2)
July 2027 (6)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-07 · NCT04841148 · CT.gov ↗
What to watch
Phase 1Glioblastoma, Recurrent Disease, Recurrent GlioblastomaRecruiting
Est. primary completion 2027-07-01 · NCT05432518 · CT.gov ↗
What to watch
Phase 1Solid TumorsActive not recruiting
Est. primary completion 2027-07-27 · NCT05238922 · CT.gov ↗
What to watch
Phase 1HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-07-31 · NCT03332797 · CT.gov ↗
What to watch
Phase 1HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-07-31 · NCT04360941 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-07-31 · NCT03304080 · CT.gov ↗
What to watch
August 2027 (1)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-08-04 · NCT06188520 · CT.gov ↗
What to watch
September 2027 (3)
Phase 1/2Esophagus CancerRecruiting
Est. primary completion 2027-09 · NCT06753747 · CT.gov ↗
What to watch
Phase 2Cancer, Tumors, Neoplasm, NeoplasiaRecruiting
Est. primary completion 2027-09 · NCT02925234 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-09-01 · NCT04985266 · CT.gov ↗
What to watch
October 2027 (3)
Phase 1HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2027-10 · NCT06941142 · CT.gov ↗
What to watch
Phase 2Metastatic Renal Cell Carcinoma, Metastatic Renal Cancer, Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma, Kidney Cancer …Recruiting
Est. primary completion 2027-10-01 · NCT07123090 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-10-31 · NCT04563507 · CT.gov ↗
What to watch
November 2027 (2)
December 2027 (7)
Phase 1HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-12 · NCT05683418 · CT.gov ↗
What to watch
Phase 2Esophageal Squamour Cell CancerNot yet recruiting
Est. primary completion 2027-12 · NCT07191977 · CT.gov ↗
What to watch
Phase 1Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia …Active not recruiting
Est. primary completion 2027-12-31 · NCT03132454 · CT.gov ↗
What to watch
Phase 1Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid NeoplasmRecruiting
Est. primary completion 2027-12-31 · NCT04693468 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-12-31 · NCT04567420 · CT.gov ↗
What to watch
Phase 2Rare TumourNot yet recruiting
Est. primary completion 2027-12-31 · NCT06692491 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-12-31 · NCT02465060 · CT.gov ↗
What to watch
2028 (14)
January 2028 (2)
February 2028 (2)
April 2028 (1)
Phase 3HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2028-04-20 · NCT06065748 · CT.gov ↗
What to watch
May 2028 (1)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-05-01 · NCT07002177 · CT.gov ↗
What to watch
June 2028 (1)
Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2028-06-30 · NCT02942355 · CT.gov ↗
What to watch
July 2028 (2)
August 2028 (3)
Phase 1/2Well Differentiated Liposarcoma, Dedifferentiated Liposarcoma, Liposarcoma, Myxoid Liposarcoma, Round Cell Liposarcoma …Recruiting
Est. primary completion 2028-08-19 · NCT06843967 · CT.gov ↗
What to watch
Phase 2Exocrine Pancreas Carcinoma, Malignant Solid Neoplasm, Ovarian Low Grade Serous Adenocarcinoma, Stage IV Ovarian Cancer AJCC v8 …Active not recruiting
Est. primary completion 2028-08-26 · NCT05554367 · CT.gov ↗
What to watch
Phase 3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-08-31 · NCT06377852 · CT.gov ↗
What to watch
September 2028 (1)
Phase 2Metastatic Malignant Neoplasm to Brain, Recurrent Brain Metastases, Progressive Brain MetastasesRecruiting
Est. primary completion 2028-09-01 · NCT02896335 · CT.gov ↗
What to watch
December 2028 (1)
Phase 1HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-12-14 · NCT06997029 · CT.gov ↗
What to watch
2029 (9)
February 2029 (1)
Phase 3HPV-unrelated Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2029-02-28 · NCT04966481 · CT.gov ↗
What to watch
March 2029 (1)
Phase 3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2029-03-31 · NCT06757634 · CT.gov ↗
What to watch
May 2029 (2)
June 2029 (1)
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2029-06-15 · NCT07748208 · CT.gov ↗
What to watch
July 2029 (2)
2030 (4)
July 2030 (3)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2030-07 · NCT05768139 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2030-07-01 · NCT05564377 · CT.gov ↗
What to watch
Phase 3HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2030-07-04 · NCT07683754 · CT.gov ↗
What to watch
September 2030 (1)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2030-09-30 · NCT03424005 · CT.gov ↗
What to watch
2038 (1)
December 2038 (1)
Phase 2Metastatic Colorectal CancerRecruiting
Est. primary completion 2038-12-31 · NCT05725200 · CT.gov ↗
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.